This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-38C13 Id scFv to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the 38C13 Id as well as the biological activity of IL2. scFvS5A8-(IL2) had a short life and was eliminated 20-fold faster than chS5A8-(IL2), failed to confer protection suggesting the relevance of the Fc effector functions such as ADCC in anti-tumor activity against 38C13. This immunocytokine was a useful tool for the study of the mechanisms of protective immunity to B cell lymphoma and for the evaluation of different therapeutic approaches based on the stimulation or suppression of the immune response.
Download resources about recombinant antibody development and antibody engineering to boost your research.
There are currently no Customer reviews or questions for ACFP-SH027. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.